

**FOR ANIMAL TREATMENT ONLY
RESTRICTED VETERINARY
MEDICINE**

**Loxicom 0.5 mg/ml
Oral Suspension**

**READ THE ENTIRE LABEL
BEFORE USE**

PRESENTATION:

Loxicom 0.5 mg/ml Oral Suspension is a pale yellow suspension for oral administration containing 0.5 mg **MELOXICAM** per mL, available in 15 mL or 30 mL multi-dose bottles with a screw cap.

ACTION:

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It inhibits leukocyte infiltration into inflamed tissue and prevents bone and cartilage destruction. To a minor extent it also inhibits collagen induced thrombocyte aggregation.

INDICATIONS:

Loxicom 0.5 mg/ml Oral Suspension is a non-steroidal anti-inflammatory drug (NSAID) for use in cats and dogs. It is indicated for the alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders such as disco-spondylosis, arthropathy and soft tissue injuries.

CONTRAINDICATIONS:

The safety of the product has not been established in pregnant or lactating cats.

DO NOT USE in pregnant or lactating bitches in the last third of pregnancy.

The use of the product is contra-indicated in animals suffering from cardiac, hepatic or clinical renal disease. Especially older cats considered for chronic treatment should be screened for pre-existing renal, hepatic or gastrointestinal disorders or hypovolaemia (using haematology, serum bio-chemical analysis and urinalysis as necessary), before administration of Loxicom 0.5 mg/ml Oral Suspension.

This is also the case where there is the possibility of gastro-intestinal ulceration or bleeding, or where there is evidence of a haemorrhagic disorder or individual hypersensitivity to the product.

PRECAUTIONS:

As for all NSAIDs use in animals less than 6 weeks of age or in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided careful clinical management may be required.

Loxicom 0.5 mg/ml Oral Suspension should not be administered concurrently with steroidal or other non-steroidal anti-inflammatory drugs, aminoglycoside antibiotics or anti-coagulant agents. Concurrent administration of potential nephrotoxic drugs should be avoided. Pre-treatment with anti-inflammatory drugs may result in additional or increased adverse effects and accordingly a treatment free period should be observed for at least 24 hours before commencing with Loxicom 0.5 mg/ml Oral Suspension. The treatment-free period, however should take into account the pharmacokinetic properties of the drugs used previously.

SIDE EFFECTS:

Typical adverse reactions of NSAIDs may occur (particularly within the first 5-14 days of treatment). These may include loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy and renal failure. Gastrointestinal side effects are in most cases transient and disappear following termination of treatment but in rare cases may be serious. If gastrointestinal side effects are persistent or of severity, treatment should be discontinued. In case of overdosing a symptomatic treatment should be initiated.

DOSAGE & ADMINISTRATION:

Shake well before use. Should be administered orally either mixed with food or directly into the mouth around meal times.

Cats:

On the first day of treatment a single dose of 0.1 mg/kg bodyweight (0.2 mL/kg bodyweight) should be given.



Treatment is to be continued once daily by oral administration (at 24 hour intervals) at maintenance dose of 0.05 mg/kg bodyweight (0.1 mL/kg bodyweight).

Particular care should be given with regard to the accuracy of dosing, and suspension should be carefully measured. Two syringes have been provided in the package to allow for accurate control of dosage, each has a kg-bodyweight scale designed for the maintenance dose (ie. 0.05 mg/kg bodyweight). Thus twice the volume should be administered on the first day as the initial dose.

Initial dose

0.1 mg/kg bodyweight
(0.2 mL/kg bodyweight)
2 maintenance dosage volumes
(as shown on syringe).

Maintenance dose

0.05 mg/kg bodyweight
(0.1 mL/kg bodyweight)
1 maintenance dosage volume
(as shown on syringe).

Dogs:

On the first day of treatment a single dose of 0.2 mg/kg bodyweight (0.4 mL/kg bodyweight) should be given. Treatment is to be continued once daily by oral administration (at 24 hour intervals) at maintenance dose of 0.1 mg/kg bodyweight (0.2 mL/kg bodyweight).

Particular care should be given with regard to the accuracy of dosing, and suspension should be carefully measured. Two syringes have been provided in the package to allow for accurate control of dosage, each has a kg-bodyweight scale designed for the maintenance dose (ie. 0.1 mg/kg bodyweight). Thus twice the volume should be administered on the first day as the initial dose.

Initial dose

0.2 mg/kg bodyweight
(0.4 mL/kg bodyweight)
2 maintenance dosage volumes
(as shown on syringe).

Maintenance dose

0.1 mg/kg bodyweight
(0.2 mL/kg bodyweight)

1 maintenance dosage volume
(as shown on syringe).
If no improvement is noticeable after 10 days of treatment, please consult a veterinary surgeon.

USER SAFETY:

People with known hypersensitivity to NSAIDs should avoid contact with meloxicam.

Meloxicam is contraindicated in women who are pregnant. Due to the risk of accidental self-injection, women who are pregnant should not administer injectable forms of meloxicam.

Hands should be washed after use. If the medicine comes into contact with the skin, the affected area should be rinsed thoroughly.

OVERDOSE:

In case of an overdose, symptomatic treatment should be initiated.

STORAGE:

Store below 25°C.
Once vial is broached, use contents within 6 months or discard.

KEEP OUT OF REACH OF CHILDREN

Disposal:

Preferably dispose of product by use. Otherwise dispose of product, packaging and waste at an approved landfill or equivalent facility.

RESTRICTED VETERINARY MEDICINE

Registered pursuant to the ACVM Act 1997 No. A10401

See www.foodsafety.govt.nz for registration conditions.

Registered to & distributed by:
Norbrook NZ Ltd.,
KPMG Centre,
18 Viaduct Harbour Avenue,
Auckland.
Ph: 0800 224 022

Manufactured by
Norbrook Laboratories Ltd.,
Station Works, NEWRY,
Co. Down, Northern Ireland.



Norbrook®

020460105